Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MGTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Botaretigene Sparoparvovec | X-Linked Retinitis Pigmentosa | Phase 3 · NCT04794101 | Active not recruiting |
| Genetic: AAV5-hRKp.RPGR | X-Linked Retinitis Pigmentosa | Phase 3 · NCT04671433 | Completed |
| AAV - CNGB3 | Achromatopsia | Phase 1/2 · NCT03001310 | Completed |
| adeno-associated virus vector AAV- CNGA3 | Achromatopsia | Phase 1/2 · NCT03758404 | Completed |
| AAV RPE65 | Leber Congenital Amaurosis | Phase 1/2 · NCT02781480 | Completed |
| AAV2hAQP1: 1 x 10^12 vg/gland (both glands) | Radiation-Induced Parotid Gland Hypofunction | Phase 1 · NCT04043104 | Completed |
| AAV2hAQP1: 3 x 10^10 vg/gland (both glands) | Radiation-Induced Parotid Gland Hypofunction | Phase 1 · NCT04043104 | Completed |
| AAV2hAQP1: 3 x 10^11 vg/gland (both glands) | Radiation-Induced Parotid Gland Hypofunction | Phase 1 · NCT04043104 | Completed |
| AAV2hAQP1: 3 x 10^12 vg/gland (single gland) | Radiation-Induced Parotid Gland Hypofunction | Phase 1 · NCT04043104 | Completed |
| AAV2hAQP1: 1 x 10^11 vg/gland (both glands) | Radiation-Induced Parotid Gland Hypofunction | Phase 1 · NCT04043104 | Completed |
| Cetoquagene Parvec | Squamous Cell Head and Neck Cancer | Phase 1 · NCT02446249 | Completed |
| Prior exposure to AAV-CNGA3 or AAV-CNGB3 | Achromatopsia | N/A · NCT03278873 | Terminated |
| AAV OPTIRPE65 | Leber Congenital Amaurosis (LCA) | N/A · NCT02946879 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MGTX holds $143.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $10.4M/quarter from operations, an estimated runway of 41.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 22 · Moderate
Based on our cash, cash equivalents, accounts receivable, accounts receivable – related party, unbilled receivables – related party, unbilled receivables and tax incentive receivable at September 30, 2026, together with the additional $95.0 million upfront payment due from Hologen and associated reimbursements, we…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MGTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC Director, 10% owner · +360,000 options |
Insider | 11,742,117 | 12.01% | 2026-04-17 |
| Rubric Capital Management LP | Institution (13G, 5%+) | 8,427,279 | 8.62% | 2026-09-30 |
| Alexandria Forbes PRESIDENT & CEO, Director · +980,000 options |
Insider | 1,325,695 | 1.36% | 2026-08-18 |
| Richard Giroux CFO & COO · +980,000 options |
Insider | 942,682 | 0.96% | 2026-10-20 |
| Stuart Naylor CHIEF SCI OFCR, OPHTHALMOLOGY · +70,000 options |
Insider | 613,187 | 0.63% | 2026-10-06 |
| Keith R. Harris Director · +106,441 options |
Insider | 200,000 | 0.20% | 2026-06-10 |
| Robert K Zeldin CHIEF MEDICAL OFFICER · +100,000 options |
Insider | 172,888 | 0.18% | 2026-02-21 |
| Robert J Wollin GENERAL COUNSEL AND SECRETARY · +100,000 options |
Insider | 57,377 | 0.06% | 2026-02-21 |
| Alan Sebulsky Director · +100,000 options |
Insider | 34,500 | 0.04% | 2026-09-23 |
Share count 97,730,540 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MGTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →